Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Thompson

Physician Assistant, Medical Spartanburg, SC Physician Assistant

NPI 1942544119 CMS profile 223686

1410 John B White Sr Blvd, Spartanburg, SC 29306

Open in the dashboard

General payments

$77,734

1,342 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Thompson of Spartanburg, SC is reported in the CMS Open Payments database as having received $77,734 across 1,342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36,749 334
2024 General $19,985 306
2023 General $13,746 280
2022 General $4,759 250
2021 General $2,494 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Thompson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Christopher Thompson were reported at $36,749. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Christopher Thompson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,494 $156 $41–$563 $132
2022 $4,759 $185 $55–$649 $149
2023 $13,746 $199 $58–$717 $160
2024 $19,985 $206 $62–$740 $164
2025 $36,749 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $26,406 268 payments
  2. UCB, Inc. $23,273 69 payments
  3. Pfizer Inc. $4,613 87 payments
  4. Arcutis Biotherapeutics, Inc. $4,479 25 payments
  5. Janssen Biotech, Inc. $3,307 137 payments
  6. Sun Pharmaceutical Industries Inc. $1,989 83 payments
  7. Lilly USA, LLC $1,849 91 payments
  8. Dermavant Sciences, Inc. $1,786 52 payments
  9. Amgen Inc. $1,583 78 payments
  10. Novartis Pharmaceuticals Corporation $1,574 110 payments
  11. Other $6,874 342 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,992 25 payments
  2. Food and Beverage $25,008 1,284 payments
  3. Travel and Lodging $10,395 22 payments
  4. Consulting Fee $6,875 4 payments
  5. Education $463 7 payments
Products named General payments · program years 2021–2025
  1. Bimzelx $23,085 62 payments
  2. RINVOQ $12,507 97 payments
  3. SKYRIZI Immunology $7,900 33 payments
  4. SKYRIZI Immunology $5,820 130 payments
  5. CIBINQO $4,380 73 payments
  6. TREMFYA $3,107 118 payments
  7. VTAMA $1,908 55 payments
  8. TALTZ $1,609 77 payments
  9. Otezla $1,583 78 payments
  10. ILUMYA $1,453 63 payments
  11. Other $14,204 789 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,328

Median for Physician Assistant: 241

Drug cost

$2,201,125

Median for Physician Assistant: $4,110

Branded share of claims

22.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 27 $565,666
Dupixent Pen Dupilumab Brand 107 $531,462
Humira(Cf) Pen Adalimumab Brand 32 $319,399
Cosentyx Unoready Pen Secukinumab Brand 24 $208,192
Tremfya Guselkumab Brand 12 $158,679
Cyltezo(Cf) Adalimumab-Adbm Brand 11 $155,704
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $111,785
Sotyktu Deucravacitinib Brand 14 $87,472
Fluorouracil Generic 226 $13,813
Oracea Doxycycline Monohydrate Brand 11 $9,782

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$771,655

Of which drugs: $517,455

Medicare patients

1,296

Average age 75

Services billed

9,555

579 women, 717 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Chronic kidney disease 30%
Diabetes 29%
Ischemic heart disease 23%
Depression 19%
Cancer 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 14 4,400 $473,223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$7,859 — —
SKYRIZI
$4,520 27 —
Bimzelx
$2,203 — —
TREMFYA
$1,494 12 —
SOTYKTU
$483 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record